Submission of Matters to a Vote of Security Holders – Form 8-K
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
| 1-15787 | 13-4075851 | |
| (Commission File Number) |
( Identification No.) |
| 10166-0188 | ||
| (Address of Principal Executive Offices) | ( |
(212)578-9500
(Registrant's Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-Kfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencementcommunications pursuant to Rule 14d-2(b)under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencementcommunications pursuant to Rule 13e-4(c)under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading |
|
||
| Common Stock, par value |
MET | |||
| Floating Rate Non-CumulativePreferred Stock, Series A, par value |
||||
| Depositary Shares, each representing a 1/1,000th interest in a share of 5.625% Non-CumulativePreferred Stock, Series E | MET PRE | |||
| Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-CumulativePreferred Stock, Series F | MET PRF |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2of the Securities Exchange Act of 1934 (§240.12b-2of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
At
| • |
elected fourteen Directors, each for a term expiring at the Company's 2024 annual meeting of shareholders; |
| • |
ratified the appointment of |
| • |
approved, on an advisory basis, the compensation paid to the Company's Named Executive Officers as disclosed in the Company's 2023 Proxy Statement; and |
| • |
voted, on an advisory basis, on the frequency of future advisory votes to approve the compensation paid to the Company's Named Executive Officers(1). |
Election of Directors:
|
Nominee |
Votes For | Votes Against | Abstained | Broker Non-Votes | ||||||||||
|
|
599,352,249 | 41,746,668 | 562,208 | 50,118,931 | ||||||||||
|
|
636,933,996 | 4,156,916 | 570,213 | 50,118,931 | ||||||||||
|
|
612,731,886 | 28,362,831 | 566,408 | 50,118,931 | ||||||||||
|
|
635,132,969 | 5,962,597 | 565,559 | 50,118,931 | ||||||||||
|
|
633,890,945 | 7,142,691 | 627,489 | 50,118,931 | ||||||||||
|
|
613,762,698 | 27,323,208 | 575,219 | 50,118,931 | ||||||||||
|
|
639,521,355 | 1,571,626 | 568,144 | 50,118,931 | ||||||||||
|
|
634,972,418 | 6,118,826 | 569,881 | 50,118,931 | ||||||||||
|
|
639,450,751 | 1,629,530 | 580,844 | 50,118,931 | ||||||||||
|
|
637,285,843 | 3,803,700 | 571,582 | 50,118,931 | ||||||||||
|
|
626,099,466 | 14,978,161 | 583,498 | 50,118,931 | ||||||||||
|
|
636,408,135 | 4,703,203 | 549,787 | 50,118,931 | ||||||||||
|
|
628,921,163 | 11,860,321 | 879,641 | 50,118,931 | ||||||||||
|
|
631,802,586 | 9,277,966 | 580,573 | 50,118,931 |
| Votes For | Votes Against | Abstained | Broker Non-Votes | |||||||||||
|
Ratify the appointment of |
663,851,986 | 27,116,219 | 811,851 | N/A | ||||||||||
|
Advisory vote to approve the compensation paid to the Company's Named Executive Officers |
610,139,897 | 29,993,247 | 1,527,981 | 50,118,931 |
| 1 year | 2 years | 3 years | Abstained | Broker Non-Votes | ||||||||||||||
|
Advisory vote on the frequency of future advisory votes to approve the compensation paid to the Company's Named Executive Officers (1) |
635,251,006 | 506,885 | 5,104,805 | 798,430 | 50,118,931 |
| (1) |
The Company expects to disclose on Form 8-K/A its Board of Directors' determination of the frequency with which future advisory votes on executive compensation will be held. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| By: |
/s/ |
|
| Title: | Senior Vice President and Secretary |
Date:
Attachments
Disclaimer



AM Best Removes From Under Review With Developing Implications and Affirms Credit Ratings of Reserve National Insurance Company
METLIFE INC FILES (8-K) Disclosing Submission of Matters to a Vote of Security Holders
Advisor News
- Wellmark still worries over lowered projections of Iowa tax hike
- Could tech be the key to closing the retirement saving gap?
- Different generations are hopeful about their future, despite varied goals
- Geopolitical instability and risk raise fears of Black Swan scenarios
- Structured Note Investors Recover $1.28M FINRA Award Against Fidelity
More Advisor NewsAnnuity News
- How to elevate annuity discussions during tax season
- Life Insurance and Annuity Providers Score High Marks from Financial Pros, but Lag on User Friendliness, JD Power Finds
- An Application for the Trademark “TACTICAL WEIGHTING” Has Been Filed by Great-West Life & Annuity Insurance Company: Great-West Life & Annuity Insurance Company
- Annexus and Americo Announce Strategic Partnership with Launch of Americo Benchmark Flex Fixed Indexed Annuity Suite
- Rethinking whether annuities are too late for older retirees
More Annuity NewsHealth/Employee Benefits News
- Senator Alvord pushes back on constant cost increases of health insurance with full bipartisan support
- Reports Outline End Stage Kidney Disease Study Findings from University of Utah (Medicare Advantage in the US mainland and Puerto Rico): Kidney Diseases and Conditions – End Stage Kidney Disease
- New Findings on Wilson’s Disease from Alexion Summarized (Patient Burden in the Treatment of Wilson Disease in the United States: An Analysis of Real-World Health Insurance Claims Data from the Komodo database): Nutritional and Metabolic Diseases and Conditions – Wilson’s Disease
- Legal Notices
- Higher premiums, Medicare updates: Healthcare changes to expect in 2026
More Health/Employee Benefits NewsLife Insurance News
- Gulf Guaranty Life Insurance Company Trademark Application for “OPTIBEN” Filed: Gulf Guaranty Life Insurance Company
- Marv Feldman, life insurance icon and 2011 JNR Award winner, passes away at 80
- Continental General Partners with Reframe Financial to Bring the Next Evolution of Reframe LifeStage to Market
- ASK THE LAWYER: Your beneficiary designations are probably wrong
- AM Best Affirms Credit Ratings of Cincinnati Financial Corporation and Subsidiaries
More Life Insurance News